NONOF (Novo Nordisk AS) COGS-to-Revenue : 0.17 (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk AS COGS-to-Revenue?

Novo Nordisk AS's Cost of Goods Sold for the three months ended in Mar. 2025 was $1,868 Mil. Its Revenue for the three months ended in Mar. 2025 was $11,318 Mil.

Novo Nordisk AS's COGS to Revenue for the three months ended in Mar. 2025 was 0.17.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Novo Nordisk AS's Gross Margin % for the three months ended in Mar. 2025 was 83.49%.

Novo Nordisk AS COGS-to-Revenue Historical Data

The historical data trend for Novo Nordisk AS's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS COGS-to-Revenue Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.16

0.17

0.16

0.15

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.15	0.15	0.16	0.15	0.17

Novo Nordisk AS COGS-to-Revenue Calculation

Novo Nordisk AS's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6251.246	/	40774.912
	=	0.15

Novo Nordisk AS's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1868.306	/	11318.105
	=	0.17

Novo Nordisk AS (OTCPK:NONOF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Novo Nordisk AS's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1868.306 / 11318.105
	=	83.49 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Novo Nordisk AS COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OTCPK:NONOF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.